By Benjamin Chiou
Date: Friday 09 May 2025
(Sharecast News) - Shore Capital has kept a 'buy' rating on healthcare real estate firm Primary Health Properties, saying the company is "still in the mix" over the bidding war for Assura and remains the preferable alternative to the latest offer from KKR and Stonepeak.
Form 8.3 - Primary Health Properties plc | 09-May-2025 | 18:16 | RNS |
Form 8.3 - Assura plc | 09-May-2025 | 15:38 | RNS |
Form 8.3 - Primary Health Properties plc | 09-May-2025 | 15:35 | RNS |
Form 8.3 - Primary Health Properties plc | 09-May-2025 | 15:20 | RNS |
Form 8.3 - Primary Health Properties Plc | 09-May-2025 | 15:03 | RNS |
Nine property companies poised to convert to Reits | 31-Dec-2006 | Sunday Telegraph |
Questor:Primary Health Properties | 23-Nov-2011 | Telegraph |
Questor :Primary Health Properties | 20-Apr-2011 | Telegraph |
Questor : Primary Health Properties | 08-Dec-2010 | Telegraph |
Dividends are the key to a sensible investment s... | 28-Dec-2009 | Sunday Telegraph |
Questor: Primary Health Properties | 31-Aug-2009 | Sunday Telegraph |
No recent information was found.
Currency | UK Pounds |
Share Price | 101.00p |
Change Today | 0.30p |
% Change | 0.30 % |
52 Week High | 103.50 |
52 Week Low | 86.15 |
Volume | 4,083,800 |
Shares Issued | 1,336.49m |
Market Cap | £1,349.86m |
RiskGrade | 84 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Strong Buy | 2 |
Buy | 1 |
Neutral | 3 |
Sell | 0 |
Strong Sell | 0 |
Total | 6 |
Latest | Previous | |
---|---|---|
Q2 | Q1 | |
Ex-Div | 27-Mar-25 | 09-Jan-25 |
Paid | 09-May-25 | 21-Feb-25 |
Amount | 1.77p | 1.77p |
Time | Volume / Share Price |
16:44 | 20,328 @ 100.54p |
16:44 | 23,805 @ 100.54p |
16:35 | 893,882 @ 101.00p |
16:35 | 14,956 @ 101.00p |
16:35 | 232 @ 101.00p |
CFO | Richard Howell |
CEO | Mark Davies |
You are here: research